1. Neoadjuvant Chemotherapy or Adjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma.
- Author
-
Sun HB, Yan S, Liu XB, Xing WQ, Chen PN, Liu SL, Li P, Ma YX, Lerut T, Daoud A, and Jiang D
- Subjects
- Humans, Neoadjuvant Therapy, Chemotherapy, Adjuvant, Chemoradiotherapy, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Esophagectomy, Retrospective Studies, Neoplasm Staging, Esophageal Squamous Cell Carcinoma pathology, Esophageal Neoplasms drug therapy, Esophageal Neoplasms surgery
- Abstract
Background: Chemotherapy and chemoradiation have become essential adjuncts to improve the survival of patients with resectable esophageal squamous cell carcinoma (ESCC) in the perioperative period. Although preoperative treatment plus surgery is commonly used, controversy remains regarding the optimal treatment strategy for patients with locally advanced ESCC., Methods: A retrospective review of clinical stage II and III ESCC patients who underwent esophagectomy at Henan Cancer Hospital between October 2014 and October 2017 was performed. The patients were divided into a neoadjuvant chemotherapy (NAC) group and an adjuvant chemotherapy (AC) group. Propensity score matching (PSM) was used to exclude confounders. Survival was estimated using Kaplan‒Meier analysis and compared by the log-rank test. The Cox proportional hazards regression model was used for both the univariate and multivariate analyses., Results: A total of 684 patients were enrolled, including 365 (53.4%) patients in the NAC group. After PSM, 294 pairs of patients were left. NAC prolonged the OS (not reached versus 57.3 months, P = 0.002) and DFS (57.2 vs. 36.4 months, P = 0.010) and decreased the total rate of recurrence (50.1% vs. 59.2%, P = 0.025) and local recurrence (27.9% vs. 36.7%, P = 0.022) compared with AC. The multivariable analyses showed that NAC plus surgery modality was an independent predictor for improved OS (HR: 0.582, 95% CI: 0.467-0.786, P = 0.001)., Conclusion: NAC plus surgery prolonged OS and DFS, and significantly decreased the total rate of recurrence compared with surgery plus AC in patients with clinical stage II and III ESCC., (© 2023. Society of Surgical Oncology.)
- Published
- 2024
- Full Text
- View/download PDF